HKUMedXelerate2026 Top 10 Showcase: New Therapeutics for Heart Failure and Obesity

In this third edition of our HKUMedXelerate 2026 Top 10 series, we spotlight ground-breaking innovations addressing major cardiometabolic challenges along the patient pathway—from restoring cardiac function to tackling obesity and its associated metabolic complications.

Featured projects in this edition:

1. Compositions for Non-Viral Provision of LAMP2 and Their Translational Applications (Led by Prof. Hung-Fat Tse):

• Pioneering next-generation regenerative therapies for severe cardiovascular disease.
• Their proprietary LAMP2 modified RNA (modRNA) therapeutics and precision non-viral delivery platforms (including engineered exosomes, microbubbles, and MSC patches) aim to restore cardiac function.
• Having recently filed a provisional patent and signed a commercialization term sheet with Versitech, this project is accelerating bench-to-bedside translation for heart failure patients globally.

2. Unlocking the Therapeutic Potential of OB001: a First-in-Class GlycoPeptide Drug for Obesity and Associated Diseases (Led by Prof. Yu WANG):

• Developing Hong Kong's first "magic pill" to combat obesity and associated diseases.
• Building on over 25 years of research, this breakthrough first-in-class glycopeptide drug represents a significant leap forward in sustainable treatment, opening new horizons for millions worldwide struggling with weight management and metabolic health.

Stay tuned as we continue to showcase how HKUMed research transforms into scalable, global clinical applications through the HKUMedXelerate programme!

💡 Coming up next: We explore innovations in the respiratory tract featuring patient-derived airway models and a universal influenza vaccine.

#HKUMed #HKUMedTTU #HKUMedXelerate #TechnologyTransfer #BiomedicalInnovation #HeartFailure #ObesityTreatment #Cardiometabolic #HealthTech #TranslationalResearch #Innovation